DNA vaccines join the fight against COVID-19
- PMID: 35366995
- PMCID: PMC8970583
- DOI: 10.1016/S0140-6736(22)00524-4
DNA vaccines join the fight against COVID-19
Conflict of interest statement
AKB is a co-founder and reports holding shares in VaxEquity, a for-profit company that aims to develop self-amplifying RNA vaccines for infectious diseases, but is not currently actively involved in the company. VaxEquity does not produce DNA vaccines. L-GB has received honoraria from Gilead Sciences and Merck for advisory work in HIV prevention.
Comment on
-
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.Lancet. 2022 Apr 2;399(10332):1313-1321. doi: 10.1016/S0140-6736(22)00151-9. Lancet. 2022. PMID: 35367003 Free PMC article. Clinical Trial.
References
-
- Our World in Data Coronavirus (COVID-19) vaccinations. 2022. https://ourworldindata.org/covid-vaccinations?country=OWID_WRL
-
- UN Development Programme Vaccine access. https://data.undp.org/vaccine-equity/accessibility/
-
- Sheridan C. First COVID-19 DNA vaccine approved, others in hot pursuit. Nat Biotechnol. 2021;39:1479–1482. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
